PubMed Health⌕ Search

Biomedical subjects

B R Balda

Publications and source records attributed to B R Balda.

At least 19 recordsLinked to original sources
PubMed1992

[Behavior and attitude regarding skin cancer prevention and early detection in relation to current knowledge--studies of visitors to an industrial fair].

During the course of the 42nd International Trade Fair 1990 in Munich a total of 1245 visitors were interrogated with regard to their education in the early recognition of skin cancer, and their behaviour in respect of exposure to sunlight. The same persons were also subjected to melanoma screening, both with regard to special assessment of pigment lesions and inspection of the entire skin. The questionnaire showed that women were better informed than men. Approximately 87% of the questioned women had heard of the problems of melanoma, whereas only about 55% of the men belonged to the informed group. The knowledge of cancer education proved to be above average in the age group between 30 and 60 years. Persons with ample knowledge on melanoma education demonstrated more motivation to take part in cancer prevention examinations and also in examinations relating to other organ systems. Thus, the necessity of cancer screening examinations was substantially more often a matter of course among women than among men. The occurrence of skin cancer on the own body as well as its occurrence in members of one's own family does not guarantee essential knowledge on melanoma education, although in the informed group the percentage of persons directly or indirectly affected by melanoma, was higher. With regard to the behaviour towards sunlight, young people dealt more cautiously and consciously with the sun than those aged 45 and over who had exposed themselves to sunlight without exercising any caution, especially in the past.(ABSTRACT TRUNCATED AT 250 WORDS)

Adult↗
PubMed1987

[Recombinant leukocyte A interferon in metastasized malignant melanoma].

The efficacy and tolerance of recombinant leukocyte A interferon (interferon alpha-2a) in 30 patients with metastasized malignant melanoma in clinical stages III and IV were tested in a phase II study. During the first 10 weeks, the patients received 18 X 10(6) IU interferon alpha-2a i.m. daily and afterwards the same dose three times a week for a further four months. In 21 patients, the tumor growth was progressive. In six patients in clinical stage IV, there was a standstill for at least two months, and in three patients in clinical stage III, there was complete remission lasting between 12 and 16 months so far. The side effects of therapy differed in the individual patients. Fever, chills, limb pain, tiredness, nausea and lack of appetite were observed most often. All these symptoms as well as the frequently occurring leukopenia and elevation of the transaminases were especially pronounced at the beginning of therapy. They were dose-dependent, but reversible.

Adult↗
PubMed1986

[Cyclosporin A in the treatment of pemphigus foliaceus and pemphigus erythematosus].

We present the cases of two female patients with pemphigus foliaceus and pemphigus erythematosus, respectively, who did not respond to long-term azathioprine and prednisone treatment in high dosages. In both patients the skin condition improved nearly completely after therapy with cyclosporine A (3.5-6.5 mg/kg per day) in combination with prednisone (7.5-10 mg every 2 days). We did not observe any side-effects during 1 year of this therapy.

Complement C3↗
PubMed1985

[Steroid receptors in malignant melanomas].

Epidemiological and experimental investigations have led to the hypothesis that the growth of malignant melanoma is induced by hormones. The demonstration of free-hormone binding sites in melanoma tissue may help to determine the validity of this hypothesis, as receptors are necessary for the transformation of hormonal action. The DCC assay with subsequent saturation analysis was used for the demonstration of specific cytoplasmatic binding sites of steroid hormones. The presence of free-cytosolic estrogen-, progesterone- and glucocorticosteroid receptors was investigated in 50 melanoma samples from 46 patients. In 20 of the 50 specimens, free estrogen and progesterone receptors were found. Free-glucocorticosteroid receptors we found in 10 cases. The use of four fold-labeled estradiol (2,4,6,7-[3]-17 beta-estradiol) in the DCC assay produced a false-positive demonstration of free-estrogen receptors. Tyrosinase hydroxylates estradiol at the C2 level of the steroid. Using fourfold labeled estradiol, tritium is separated at the C2 position, thus forming radioactive water in the cytosol which mimics high, free-estrogen binding sites. The use of twofold-labeled estradiol or L-dopa in the experiments with fourfold labeled estradiol produced no false-positive determinations of estrogen receptors. The demonstration of receptors in malignant melanomas was unaffected by the sex of the patient. Also, the type of malignant melanoma, the invasion level, and the prognostic index did not show a correlation with the presence of the various hormone receptors. In metastases, free steroid hormone receptors were detected less often than in the primary tumor.

Breast Neoplasms↗
PubMed1983

[Malignant melanoma in lupus (tuberculosis cutis luposa)].

We report on a 72 years old man showing a strikingly fast spreading malignant melanoma developing on a lupus vulgaris which had existed since childhood. The coincidence of both diseases is obviously extremely rare. A pathogenetic relationship between melanoma and lupus vulgaris, such as claimed for carcinoma in lupo, especially after X-ray irradiation, is not inferable.

Aged↗
PubMed1980

[Allergic contact dermatitis due to tromantadin (author's transl)].

37 observations on allergic contact dermatitis due to tromantadine are reported. With the increasing distribution and application of this adamantane derivative, the incidence of this type of clinical picture will probably increase further. The attendant physician should therefore accordingly explain to his patients and inform them of the initial symptoms - presumably striking intensification and local extension of the herpes eruption in spite of intensive treatment.

Adolescent↗
PubMed1980

[Dacarbazine (DTIC) therapy and the Budd-Chiari syndrome].

A case of a 58 years old female is presented, who died because of a Budd-Chiari-syndrome. This complication had developed during treatment with Dacarbazine (DTIC), which was given after surgical removal of a malignant melanoma. The causative relation between the Budd-Chiari-syndrome and this cytostatic drug is discussed, even though the influence of other drugs cannot be excluded.

Budd-Chiari Syndrome↗